Literature DB >> 23285925

[Principle of adverse drug reaction causality judgement and interpretation of causality assessment method both in China and abroad].

Xu Wei1, Yan-Ming Xie.   

Abstract

Adverse drug reaction (ADR) causality judgement is a routine procedure in pharmacovigilance, no unified judgement standard and categories standard are established. Temporal relations, consistency, specificity, intensity of reaction are the basic principle of ADR causality jugement we should abide by. There are many ADR causality assessment methods, which classifies standard algorithms, expert judgement, bayesian approches. The implicit definitions of some categories standard, incomplete information from case reports coupled with vast differences in the application of clinical judgements are the major problems facing ADR evaluation. Almost every kind of method shares certain common feature, that is, causal relationship of ADR is classified about five categories. However, causality assessment methods differ in basic principle, evaluation standard, specificity and sensitivity. There are some advantages and disadvantages among methods, but no causality assessment method can be applied to all ADR evaluation to date.

Mesh:

Substances:

Year:  2012        PMID: 23285925

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  2 in total

1.  Safety of Recombinant Fusion Protein ESAT6-CFP10 as a Skin Test Reagent for Tuberculosis Diagnosis: an Open-Label, Randomized, Single-Center Phase I Clinical Trial.

Authors:  Feng Li; Miao Xu; Lijun Zhou; Yanqing Xiong; Lu Xia; Xiaoyong Fan; Jun Gu; Jiang Pu; Shuihua Lu; Guozhi Wang
Journal:  Clin Vaccine Immunol       Date:  2016-09-06

2.  Safety Evaluation of Recombinant Fusion Protein RP22 as a Skin Test Reagent for Tuberculosis Diagnosis: A Phase I Clinical Trial.

Authors:  Lu Xia; Xu-Hui Liu; Zhang-Yan Zhao; Tao Li; Xiu-Hong Xi; Ping Liu; Wei Huang; Xiao-Yong Fan; Xue-Qiong Wu; Shui-Hua Lu
Journal:  Infect Dis Ther       Date:  2021-04-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.